D. Medical Industries

D. Medical Industries Ltd.
Public
Traded as TASE: DMED
OTC Pink: DMEDF
Industry Medical equipment
Founded July 22, 1992 (1992-07-22)
Headquarters Tirat HaCarmel, Israel
Revenue Steady US$ 0.39 million (2011)
Decrease US$ –12.34 million (2011)
Steady US$ –12.63 million (2011)
Subsidiaries Spring Health Solutions Ltd.
Spring-Set Health Solutions Ltd.
Website dmedicalindustries.com
Footnotes / references
[1]

D. Medical Industries is a publicly traded holding company, headquartered in Israel, that develops and markets insulin pumps and infusion sets through its subsidiary, Spring-Set Health Solutions. Shares of the company are traded on the Tel Aviv Stock Exchange.

Company

D. Medical Industries develops, manufactures and markets insulin delivery devices for patients suffering from diabetes.[2] In 2010, 70% of diabetes sufferers lived in low- and middle-income countries, with the International Diabetes Federation projecting a 54% increase in the worldwide incidence of diabetes by 2030, particularly outside North America and Europe. According to the former CEO Efraim (Efri) Argaman, D. Medical's products are ideally suited for the developing world on account of their lower production costs: unlike the industry standard motor-and-gear train, D. Medical's technology is spring-based.[3]

D. Medical's competitors include Medtronic, Roche, and Insulet.[4] The company's Spring subsidiary is developing a semi-disposable hybrid patch pump that can be attached to the body or worn as a tubed pump.[5] A year after having obtained ISO 13485:2003 and ISO 9001:2008 certification from the Canadian Medical Devices Conformity Assessment System, in 2012 D. Medical signed an original equipment manufacturer agreement with a South Korea-based worldwide distributor for its Spring Universal Detach Detect Infusion Sets.[6][7]

Subsidiaries

Products

History

The company with which D. Medical was reverse-merged in 2004 was founded in 1992 as Peer Elevators and Industries (92) Ltd. (Hebrew: פאר מעליות ותעשיות (92) בע"מ‎). In 1994 Peer Elevators changed its name to Ram Tzur (or Ram Zur) Ltd. and went public on the Tel Aviv Stock Exchange. In 2001 Ram Tzur acquired the assets of Aryt Systems, a developer and manufacturer of advanced military equipment, and changed its name to Aryt Systems Ltd. In 2004 Aryt Systems, which had by that time become a shell company on the TASE Maintenance List, was acquired by Yehoshua Hershkovitz and sold to a group of investors comprising Zeev Bronfeld, Gal Erez, Eyal Sheratzky, and Meni Mor. They changed the name of the company to D. Medical Industries and used it to acquire a 73% stake in Nilimed, a Technion Entrepreneurial Incubator company.[9][10][11][12][13]

In August 2010 D. Medical executed an initial public offering in the United States, raising $10.5 million.[14] The company's shares were listed on the NASDAQ Capital Market until July 2012.

Mergers and acquisitions

In 2006 D. Medical acquired 72.99% of Nilimedix Ltd. for $1.5 million. Over time it increased its stake in the company until as of 2010 it held 100% of Nilimedix's issued and outstanding share capital.[15][16]

In 2007 D. Medical acquired 50.01% of Sindolor Medical Ltd. for $800,000. It reverse-merged the company with the shell company Sela Group and renamed it NextGen Biomed Ltd. In August 2011 D. Medical sold its stake in NextGen for $1.6 million.[15][17][18]

See also

References

  1. ↑ "DMED Income Statement". Yahoo! Finance. 2012. Retrieved 15 May 2012.
  2. ↑ "D Medical Industries Ltd.". Hoover's. Retrieved 7 November 2011.
  3. ↑ Kilmer, Stephen (24 August 2010). "D. Medical taps ROW for growth; visibility with NASDAQ listing". BioTuesdays. Retrieved 7 November 2011.
  4. ↑ "D. Medical Industries Ltd: Competition/competitors". EDGAR Online. 25 June 2010. Retrieved 7 November 2011.
  5. ↑ Tenderich, Amy (28 June 2011). "ADA Conference 2011: Product Updates". DiabetesMine. Retrieved 7 November 2011.
  6. ↑ "D Medical units win Canadian certification for diabetes devices". Globes. 27 April 2011. Retrieved 14 May 2012.
  7. ↑ "D Medical shares jump on OEM deal". Globes. 14 May 2012. Retrieved 14 May 2012.
  8. ↑ "D Medical Subsidiary Receives FDA Approval to Market its Insulin Pump". Net Resources International. medicaldevice-network.com. 3 May 2011. Retrieved 7 November 2011.
  9. ↑ "די מדיקל אינדסטריס בע"מ: דו"ח שנתי לתקופה שהסתיימה ביום 31.12.2006" [D. Medical Industries Ltd.: Annual report for period ending 31 December 2006] (PDF) (in Hebrew). Israel Securities Authority. 2007. Retrieved 7 November 2011. החברה הוקמה תחת השם פאר מעליות ותעשיות (92) בע"מ, בינואר 1994 שינתה את שמה לשם רם צור תעשיות בע"מ. בינואר 2001 שינתה החברה את השם לארית מערכות בע"מ, ובינואר 2005 שינתה החברה את שמה לשמה הנוכחי.
  10. ↑ "Nilimed to get NIS 900,000 Chief Scientist grant". Globes. 2 November 2005. Retrieved 7 November 2011.
  11. ↑ Shimoni, Eli (15 April 2005). "תחיית השלדים" [Rise of the shells]. Ynet (in Hebrew). Retrieved 7 November 2011. המשקיעים החדשים הזרימו כסף לקופת החברה ורכשו מידי חממת הטכניון כ-73% מחברת נילי מד שעוסקת בפיתוח עזרים רפואיים לטיפול בחולי סוכרת.
  12. ↑ "Hard times at Aryt". Globes. 24 February 2003. Retrieved 7 November 2011.
  13. ↑ Feldman, Batya (24 December 2006). "D-Medical files prospectus for secondary offering". Globes. IVC Research Center. Retrieved 7 November 2011.
  14. ↑ "D Medical Industries prices IPO below expectations". Bloomberg Businessweek (New York). Associated Press. 5 August 2010. Retrieved 7 November 2011.
  15. 1 2 Haft, Ziv (March 2009). "Nilimedix Ltd., Sindolor Medical Ltd." (PDF). Israel Securities Authority. p. 6. Retrieved 7 November 2011.
  16. ↑ "D. Medical Industries Ltd. Acquires Remaining Holdings in Nilimedix Ltd.". Reuters. 25 December 2010. Retrieved 7 November 2011.
  17. ↑ Kornfeld, Tomer (25 April 2010). "לא עוצרת: נקסט ג'ן זינקה 100% ב-3 ימי מסחר, פועלת להשתלט על אינטרקיור" [Won't stop: NextGen jumped 100% in three trading days, moving to gain control of InterCure]. Bizportal (in Hebrew). Retrieved 7 November 2011. בשלהי חודש ינואר השנה השלימה די מדיקל, שבשליטת זאב ברונפלד מני מור ואייל שרצקי, את רכישת חברת נקסט ג'ן לאחר שמזגה לתוכה את פעילות חברת הבת סינדולור אשר פיתחה מזרק ללא כאב.
  18. ↑ "D. Medical closes sale of NextGen Biomed". Yahoo! Finance. 3 August 2011. Retrieved 7 November 2011.

External links

This article is issued from Wikipedia - version of the Monday, March 07, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.